Semaglutide for atrial fibrillation

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Dec 2025: Trial registered, NCT07275697
  2. 23 Mar 2026: Trial started, NCT07275697

The trials

NCT07275697: Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

State
Under way
Phase
Phase 4
People
200 planned
Started
23 Mar 2026
Primary completion
30 Dec 2028
Arms
Randomized to Semaglutide
Results
None posted
  1. 10 Dec 2025: Trial registered
  2. 23 Mar 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.